Granules India shares in focus after US FDA flags observation at Telangana API facility

The US FDA issued a Form 483 observation for its Telangana API facility. While not a final non-compliance verdict, the company plans a timely response. The facility is key for paracetamol API production. The stock has fallen 19% YTD but remains a ‘Strong Buy’.